Higher Buprenorphine Dose Increases Likelihood of Staying in Treatment
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 21, 2023 -- Patients initiating buprenorphine treatment for opioid use disorder who are prescribed a 24-mg dose are more likely to remain in treatment longer than those prescribed 16 mg, according to a study published online Sept. 18 in JAMA Network Open.
Laura C. Chambers, Ph.D., from Brown University in Providence, Rhode Island, and colleagues estimated the association between buprenorphine dose and time to treatment discontinuation during a period of widespread fentanyl availability. The analysis included 6,499 patients initiating buprenorphine treatment for opioid use disorder (Oct. 1, 2016, to Sept. 30, 2020).
The researchers found that more than half of patients were prescribed a daily dose (16 mg or 24 mg) at initiation (16 mg: 50 percent; 24 mg: 10 percent). Nearly six in 10 patients (58 percent) discontinued buprenorphine treatment within 180 days (16 mg: 59 percent; 24 mg: 53 percent). Patients prescribed a dose of 16 mg had a greater risk for treatment discontinuation than those prescribed 24 mg (adjusted hazard ratio, 1.20).
"The results of this study suggest that the value of higher buprenorphine doses than currently recommended needs to be considered for improving retention in treatment," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
People With Opioid Use Disorder Less Likely to Receive Palliative Care
MONDAY, April 29, 2024 -- People with opioid use disorder (OUD) are less likely to receive palliative care during the last 90 days before death, according to a study published...
Seven in 10 Experiencing Homelessness Have a Mental Health Disorder
WEDNESDAY, April 17, 2024 -- The majority of people experiencing homelessness have mental health disorders, according to a review published online April 17 in JAMA...
Midlife Deaths of Despair Increased From 1999 to 2022
THURSDAY, April 11, 2024 -- Midlife deaths from suicide, drug overdose, and alcoholic liver disease, collectively known as deaths of despair, increased from 1999 through 2022...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.